BioSpace News Archive

BioVie Inc. announced data from a poster detailing the epigenetic basis for how in a Phase 2 exploratory biomarker study its drug candidate NE3107 may have potentially regulated specific genes in a manner significantly correlated with observed cognitive and biomarker improvements.

BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), is a commercial-stage biopharmaceutical company focused on genetic diseases and cancers.

The first-ever county-level estimates of the prevalence of people with Alzheimer’s dementia — in all 3,142 United States counties — were released at the Alzheimer’s Association International Conference® 2023, in Amsterdam, Netherlands, and online.

BioLineRx Ltd. today announced the initiation of a randomized, investigator-initiated Phase 2 clinical trial in first line metastatic pancreatic cancer based on preliminary data from the single-arm pilot phase.

Glaukos Corporation announced today that it has entered into a collaboration and marketing agreement with Radius XR, Inc.

Organon (NYSE: OGN), a global women’s healthcare company will release its second quarter 2023 financial results on August 8, 2023, prior to the company’s webcast and conference call scheduled for 8:30 a.m. EDT.

Camurus announced topline, interim data from an open-label, long-term safety and extension trial, ACROINNOVA 2, assessing CAM2029, octreotide subcutaneous depot, in 135 adult patients with acromegaly.

OrganOx Ltd, a world-leading medical technology company committed to making every donated organ count with metra®, a fully automated normothermic machine perfusion device for liver transplantation, announces that it has raised £25 million in a growth round led by Lauxera Capital Partners with support from existing investors.

EnteroBiotix Limited, a clinical stage company with the premier platform for full-spectrum microbiome therapeutics, announced the appointment to its Board of Elmar Schnee as Executive Chairman.

GeneQuantum and InxMed, a clinical-stage biotechnology company dedicates on developing innovative therapies targeting drug resistance for hard-to-treat solid tumors, signed a collaboration agreement.